数字乳腺断层合成与全视野数字乳腺X线摄影筛查中召回的单视角不对称性结局比较
本回顾性研究比较了2016年7月14日至2020年7月14日间DBT与FFDM筛查中因单视角不对称性召回者的结局。DBT筛查不对称性召回率低于FFDM(2.5% vs 3.4%,p<.001),但召回后恶性率均为1.7%,无差异。DBT召回的不对称性中,年龄≥55岁和乳腺密度不高是不受其他因素影响的恶性预测因素。
要点
- DBT筛查不对称性召回率2.5%(3169/128755),低于FFDM的3.4%(815/23898),p<.001。
- DBT与FFDM召回不对称性的恶性率均为1.7%,无显著差异(p>.99)。
- DBT召回不对称性中,年龄55-69岁OR=2.40(p=.04)、≥70岁OR=7.93(p<.001),乳腺密度不高OR=2.47(p=.001)为恶性独立预测因素。
核心结论
- DBT筛查中因不对称性召回者较FFDM少见,两种模态召回不对称性的恶性率均低(1.7%);年龄≥55岁和乳腺密度较低可预测DBT召回不对称性的恶性。
研究设计与样本
- 回顾性研究,分析2016年7月14日至2020年7月14日期间DBT与FFDM筛查中因单视角不对称性召回者;进一步分析完成诊断性检查和后续随访的患者,DBT组3119例(平均年龄57岁),FFDM组811例(平均年龄56岁)。
关键影像表现/征象
- 最终BI-RADS分类分布在两种模态间无差异(p>.99)。
- FFDM召回恶性不对称性较DBT更常伴诊断性检查时的结构扭曲(35.7% [5/14] vs 9.3% [5/54],p<.001)。
- FFDM召回恶性不对称性更多为浸润性导管癌(92.9% vs 57.4%),更少为浸润性小叶癌(0.0% vs 24.1%)(p=.05)。
诊断标准与关键数值
- DBT筛查不对称性召回率2.5%(3169/128755),FFDM为3.4%(815/23898),DBT较低(p<.001)。
- DBT召回不对称性恶性率1.7%(54/3119),FFDM为1.7%(14/811),无显著差异(p>.99)。
- DBT召回不对称性恶性独立预测因素:年龄55-69岁OR=2.40(p=.04),≥70岁OR=7.93(p<.001),参照<55岁;乳腺密度不高OR=2.47(p=.001),参照致密乳腺。
临床应用与阅片要点
- 作者结论支持使用DBT减少不必要的召回,且不改变不对称性相关恶性的阳性预测值。
- 作者认为评估DBT筛查中的潜在不对称性时,应考虑患者因素以判断是重叠纤维腺体组织还是需诊断性检查的可疑发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Recall rates are lower for digital breast tomosynthesis (DBT) than for full-field digital mammography (FFDM). This difference could have important implications with respect to one-view asymmetries given that missed cancers are often visible on one view. OBJECTIVE. The purpose of this study is to compare the outcomes of one-view asymmetries recalled from DBT versus FFDM screening examinations and to determine predictors of malignancy among recalled asymmetries. METHODS. This retrospective study first determined recall rates associated with one-view asymmetries for screening mammography performed using DBT and FFDM from July 14, 2016, through July 14, 2020. Further analyses included patients recalled for a one-view asymmetry who completed subsequent diagnostic workup and all recommended follow-up. Patient and cancer characteristics were extracted from the electronic health record. RESULTS. The recall rate associated with asymmetries was lower for DBT screening (2.5% [3169/128,755]) than for FFDM screening (3.4% [815/23,898]) (p < .001). Further analyses of patients who completed diagnostic workup and subsequent follow-up included 3119 patients (mean age, 57 years) for DBT screening and 811 patients (mean age, 56 years) for FFDM screening. Distribution of final BI-RADS categories from subsequent diagnostic workup was not different between the two modalities (p > .99). The frequency of malignancy was not different between asymmetries recalled from DBT (1.7% [54/3119]) and FFDM (1.7% [14/811]) (p > .99). Malignant asymmetries identified on FFDM versus DBT were more frequently associated with architectural distortion on diagnostic workup (35.7% [5/14] vs 9.3% [5/54]) (p < .001) and were more commonly invasive ductal carcinoma (92.9% vs 57.4%) and less commonly invasive lobular carcinoma (0.0% vs 24.1%) (p = .05). In multivariable analysis, independent predictors of malignancy among recalled asymmetries from DBT were age (for 55-69 years, odds ratio [OR] = 2.40 [p = .04]; for ≥ 70 years, OR = 7.93 [p < .001]; reference, < 55 years) and breast density (not dense, OR = 2.47 [p = .001]; reference, dense breasts). CONCLUSION. Recalled asymmetries were less frequent for DBT than for FFDM. The malignancy rate was low for both modalities (1.7%). Age 55 years old and older and lower breast density predicted malignancy for DBT-recalled asymmetries. CLINICAL IMPACT. Our results support the use of DBT to reduce unnecessary recalls without altering PPV for asymmetry-associated malignancies. Patient factors should be considered when assessing whether a potential asymmetry on DBT screening represents overlapping fibroglandular tissue or a suspicious finding that requires diagnostic workup.
引用
- Gong, Nguyen, Lee, et al. Comparison of Outcomes for One-View Asymmetries Recalled From Digital Breast Tomosynthesis Versus Full-Field Digital Mammography Screening Examinations. AJR Am J Roentgenol. 2022. PMID: 35703412. doi:10.2214/AJR.22.27820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。